Supreme Court nixes Abilify patent challenge; Can Bayer keep accelerating now that Eliquis is approved?;

@FiercePharma: Here's a novel job-preserving approach: U.K. politician urges NHS to use more of $AZN's Brilinta to stave off job cuts. More | Follow @FiercePharma

 @AlisonBFierce:Who gave you the flu? A new Facebook app helps you place the blame. Article | Follow @AlisonBFierce

> The U.S. Supreme Court turned away an appeal by generics maker Apotex, which had been challenging a patent on Abilify, the blockbuster antipsychotic marketed by Otsuka Pharmaceuticals and Bristol-Myers Squibb ($BMY). Report

> After an unusually strong 2012, can Bayer keep the ball rolling--especially now that Pfizer ($PFE) and Bristol-Myers Squibb have won approval for their Xarelto challenger Eliquis? Report

> The U.K.'s cost-effectiveness watchdog is opening up on preventive use of breast cancer drugs such as Tamoxifen. Report

> A U.K. politician urged the National Health Service to use more of AstraZeneca's ($AZN) blood thinner Brilinta as a way to keep the drugmaker's payroll from shrinking further. Report

> Indian pharma growth slowed during the quarter ended Dec. 31 for the first time in two years. Report

Medical Device News

 @FierceMedDev: ArthroCAD draws Series A for surgical device development. Story | Follow @FierceMedDev

@MarkHFierce: Given Imaging ended exploration of a possible sale or merger--for now, the PillCam maker will go it alone. More | Follow @MarkHFierce

 @DamianFierce: Covidien wants to see if its Hawk devices can work in combo PAD treatment, a potentially lucrative market. Report | Follow @DamianFierce

> Saliva gland could be secret to a Parkinson's disease Dx. Story

> St. Jude hit with FDA warning letter over Durata manufacturing. News

Biotech News

 @FierceBiotech: Roche picks Sanford-Burnham chief to revive lagging research group. Story | Follow @FierceBiotech

@JohnCFierce: Looks like Mene Pangalos, champion of virtual development, eliminating fixed costs, comes out on top of AZ R&D. Release | Follow @JohnCFierce

@RyanMFierce: Pharma's got blockbuster hopefuls on the move in 2013, but a special lack of Alzheimer's meds in the mix. More | Follow @RyanMFierce

> Versartis pockets $25M C round as it looks to PhII growth hormone study. Article

> Analysts pick the top blockbuster drug prospects in the class of '13. Report

> AstraZeneca research chief Mackay ousted in executive shakeup. News

Biotech Research News

> Stem cells cut heart damage in muscular dystrophy mice. News

> Targeting VEGF could do more harm than good in the eye. More

> Stem cells show early promise in ALS. Item

Pharma Manufacturing News

> Private equity firm lays out $212 million for API maker. News

> Spain's Idifarma sweats the small stuff. Story

> New manufacturing issues lead AbbVie to 2nd Synthroid recall. Article

> Stem cells show early promise in ALS. More

And Finally... Can high-tech gadgets improve your posture and perfect your golf swing? Report (sub. req.)

 

Suggested Articles

A few months ago, Sanofi tapped its chief medical officer Ameet Nathwani, M.D., to spearhead a digital revolution at the company.

As Bayer management predicted, it seems as though the German conglomerate’s for-sale animal health business has indeed attracted high interest.

Roche has its first global approval for Rozlytrek, a drug that targets NTRK fusion-positive tumors and one that will challenge Bayer's Vitrakvi.